

Metcela Inc. announces its latest developments in innovative cell therapy for heart failure using a specific subpopulation of fibroblasts found in the heart, called VCAM-1-positive cardiac fibroblasts (VCF).

Metcela Inc. is a clinical-stage biotech start up based at KINGSKY FRONT Japan. The company is developing innovative methods for treating heart failure.

In July 2021 Metcela Inc. announced the initiation of phase 1 investigator-initiated clinical trial of MTC001, cell and delivery device combination product, in patients with chronic ischemic heart failure. Metcela Inc. has partnered up with Japan Lifeline Co., Ltd. (JLL) for the development of a new cell-delivery catheter. The clinical trial is being conducted at the University of Tsukuba Hospital with Metcela supplying MTC001.

In October 2021 Metcela Inc. was selected as one of the two elected candidates for the Tokyo Metropolitan Government's acceleration program, "Deep Ecosystem". This program will further support the company's global expansion efforts.

Furthermore, Metcela participated in BioJapan 2021, from October 12 to 14, held at PACIFICO Yokohama, - "Asia's largest partnering event consisting of exhibitions, seminars, and partnering programs". Kenichi Nogami, the co-CEO of Metcela, was invited to speak on the topic of "Efforts of university-launched venture companies, from the field of regenerative medicine". Metcela also participated virtually in the Cell & Gene Meeting on the MESA. Metcela continues to put effort into attending these partnering events to accelerate their business.

In November 2021 Metcela's Co-CEO, Takahiro Iwamiya will present an ePoster (#P2496) at American Heart Association (AHA) Scientific Session 2021 entitled, "Heterogeneity and Plasticity of Cardiac Fibroblasts Governing Reparative Lymphangiogenesis After Myocardial Infarction: A New Therapeutic Approach for Heart Failure".

Metcela is continuously search for highly motivated and talented individuals interested in working at an upcoming Japanese regenerative medicine start-up. For more information, please contact the company for a casual conversation

Press enquiries

Public relations

Ami Okuno

Email: info@metcela.com, Tel:81-44-201-1376

Metcela Inc., LIC Lab/Office, Life Innovation Center 3-25-22Tonomachi, Kawasaki-ku,Kawasaki-shi, Kanagawa 210-0821.

Further information

Related links

Initiation of a Phase I Clinical Trial of MTC001 in Patients with Chronic Ischemic Heart Failure | Metcela Inc.

https://www.metcela.com/en/2021/07/14/ph1trial_eng/

Abstract of the ePoster to be given at American Heart Association (AHA) Scientific Session 2021

https://www.abstractsonline.com/pp8/?_ga=2.66833582.164123871.1634520327-36521822.1629693119#!/9349/session/1060

Metcela Inc website

<https://www.metcela.com/en/>